Why the study?
What are the rates of adverse events (death, non-fatal MI, emergency revascularization) in patients awaiting myocardial revascularization?
What are the rates of adverse events (death, non-fatal MI, emergency revascularization) in patients awaiting myocardial revascularization?
Countries without treatment recommendations for waiting times should consider introducing maximum wait times to limit adverse events, especially for CABG.
Answers are grounded in this paper and cite their sources.
May justify maximum wait-time policies for revascularization; extends meta-analytic evidence on risks, especially for CABG.
Rates of death, non-fatal MI and emergency revascularization when awaiting myocardial revascularization are infrequent but higher in specific patients. Countries that not yet have treatment recommendations related to waiting times should consider introducing a maximum to limit adverse events, particularly when awaiting CABG.
No takes yet. Share an insight, caveat, or question.
Head et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: